SPRB (Spruce Biosciences Inc.) Earnings per share for the last four quarters

Spruce Biosciences, Inc. (SPRB) - corporate logo

Spruce Biosciences (SPRB) is implementing breakthrough methods for hormone correction at the genetic level, and the historical YoY EPS growth over the last 12 months on GURU.Markets yields 59.20, which expresses the metric's value today. High pricing power is driven by the uniqueness of tildacerfone amid inelastic demand. However, a cash deficit and failed tests are forcing the company to aggressively optimize expenses to maintain liquidity.

SPRB Spruce Biosciences Inc. Net earnings per share (EPS TTM) (02/11/2024 - 11/16/2026)

SPRB (Spruce Biosciences): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:SPRB (Spruce Biosciences Inc.)
Core merchandise of Spruce Biosciences Inc.

Spruce Biosciences invests in clinical trials for rare hormonal pathology therapies through partnerships with endocrinology centers. R&D expenses for such developments directly impact net income, which forms the basis for calculating earnings per share. This indicator measures the annual change in EPS over the last 12 months, eliminating the blind spots of quarterly reporting. Analyzing the annual EPS TTM delta allows for an assessment of the issuer's financial resilience to crises. The trend along this curve helps investors recognize the risk of overpaying for the asset in a timely manner.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months lexpharma.com LXRX|Net earnings per share (EPS TTM) MBX (MBX Biosciences)|Altimmune Corp - Earnings per share for the last twelve months|Aardvark Therapeutics Inc. - Net earnings per share (EPS TTM)|SGMT - Net earnings per share (EPS TTM)|BioAge Labs (BIOA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months biomeafusion.com (BMEA)|Earnings per share for the last twelve months Quince Therapeutics, Inc.|Net earnings per share for the last 12 months Fractyl (GUTS)|Net earnings per share for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Net earnings per one share for the last twelve months|Pluri Inc. - Net earnings per share for the last 12 months|Net earnings per share for the trailing year Synlogic Corp|LPCN - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Matinas BioPharma Holdings, Inc. MTNB|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS